Advances in the treatment of soft tissue sarcoma: Focus on eribulin

Panagiotis Koliou, Vasilios Karavasilis*, Maria Theochari, Seth M. Pollack, Robin L. Jones, Khin Thway

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed. In this article, we reviewed evidence from the latest published data on eribulin and its use in the treatment of soft tissue sarcomas. We explored the drug’s mechanism of action, pharmacodynamics, pharmacokinetics, and metabolism. Lastly, we reviewed all preclinical studies as well as clinical trials that investigated eribulin.

Original languageEnglish (US)
Pages (from-to)207-216
Number of pages10
JournalCancer Management and Research
StatePublished - 2018
Externally publishedYes


  • Chemotherapy
  • Eribulin
  • Sarcoma

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Advances in the treatment of soft tissue sarcoma: Focus on eribulin'. Together they form a unique fingerprint.

Cite this